MaaT Pharma announced that promising clinical data for its drug candidates, MaaT013 and MaaT033 will be reported in two oral presentations by Pr. 12-month overall survival was 59% in patients responding to MaaT013 treatment. A 65% ORR was observed in 31 patients treated with MaaT013 as 3rd-line therapy after failure to 2nd-line rruxolitinib treatment; 12-month overall survival in this group responding to MaaT033 treatment was 74%; similar patient population is being treated in MaaT Pharma's ongoing pivotal Phase 3 ARES clinical trial in Europe.

Key clinical findings with MaaT033 in Phase 1b study CIMON - MaaT033 was shown to be safe and tolerable in 21 patients; 4 severe adverse events were reported in 4 patients, only one was considered as possibly related to the treatment by the investigator. Treatment with MaaT033 induced increased microbiota richness as well as strong and persistent engraftment in cohorts 3 and 4 of the dose escalation study, which consisted of taking 3 capsules of the drug candidate per day. Engraftment following MaaT033 treatment correlated with increased anti-inflammatory marker levels and reduced inflammatory marker levels in patients.

MaaT Pharma is preparing a randomized, double-blind, placebo-controlled pivotal Phase 2b clinical trial for MaaT033; trial start is expected in second quarter 2023 as previously announced.